|
Volumn 95, Issue 5, 2002, Pages 305-311
|
The cost utility of bisphosphonate treatment in established osteoporosis
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BISPHOSPHONIC ACID DERIVATIVE;
RISEDRONIC ACID;
AGE;
AGED;
ARTICLE;
CLINICAL TRIAL;
COHORT ANALYSIS;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
COST BENEFIT ANALYSIS;
COST CONTROL;
COST EFFECTIVENESS ANALYSIS;
COST OF ILLNESS;
COST UTILITY ANALYSIS;
FEMALE;
HIP FRACTURE;
HUMAN;
LIFESPAN;
MAJOR CLINICAL STUDY;
OUTCOMES RESEARCH;
POSTMENOPAUSE OSTEOPOROSIS;
PRIORITY JOURNAL;
QUALITY ADJUSTED LIFE YEAR;
RANDOMIZED CONTROLLED TRIAL;
SENSITIVITY ANALYSIS;
STOCHASTIC MODEL;
UNITED KINGDOM;
|
EID: 0036105480
PISSN: 14602725
EISSN: None
Source Type: Journal
DOI: 10.1093/qjmed/95.5.305 Document Type: Article |
Times cited : (46)
|
References (25)
|